10-QPeriod: Q1 FY2015

GILEAD SCIENCES, INC. Quarterly Report for Q1 Ended Mar 31, 2015

Filed May 8, 2015For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) reported a strong first quarter for 2015, demonstrating significant revenue growth driven by its highly successful Hepatitis C (HCV) franchise, particularly Harvoni and Sovaldi. Total revenues reached $7.6 billion, a substantial increase from $5.0 billion in the prior year's quarter, with HCV product sales alone contributing $4.6 billion. The company also showed robust performance in its HIV product sales, which grew by 9% year-over-year, bolstered by single-tablet regimens like Stribild and Complera/Eviplera. This strong top-line performance translated into a significant jump in net income to $4.3 billion ($2.76 per diluted share) from $2.2 billion ($1.33 per diluted share) in the first quarter of 2014. Financially, Gilead maintained a strong liquidity position with over $14.5 billion in cash, cash equivalents, and marketable securities. The company actively returned capital to shareholders, completing a $3.0 billion stock repurchase program and announcing a new $15.0 billion program, alongside the initiation of its first quarterly dividend. However, investors should note ongoing legal proceedings and potential competition, particularly in the HCV market, as key areas to monitor.

Financial Highlights

54 data points
Beta

Revenue

$7.59B

85.9% Gross Margin

Net Income

$4.33B

57.1% Net Margin

EPS (Diluted)

$2.76

Total Assets

$38.32B

Cash & Equivalents

$10.63B

Free Cash Flow

$5.70B

Financial Statements
Beta
Revenue$7.59B
Cost of Revenue$882.00M
Gross Profit$6.52B
R&D Expenses$696.00M
SG&A Expenses$645.00M
Operating Expenses$2.22B
Operating Income$5.37B
Interest Expense$153.00M
Net Income$4.33B
EPS (Basic)$2.91
EPS (Diluted)$2.76
Shares Outstanding (Basic)1.49B
Shares Outstanding (Diluted)1.57B

Key Highlights

  • 1Total revenues surged to $7.6 billion for Q1 2015, a 52% increase year-over-year, primarily driven by strong HCV product sales.
  • 2Hepatitis C (HCV) product sales (Harvoni and Sovaldi) generated $4.6 billion, representing a 100% increase year-over-year and accounting for a significant portion of total revenue.
  • 3Net income attributable to Gilead more than doubled, reaching $4.3 billion ($2.76 per diluted share) in Q1 2015, up from $2.2 billion ($1.33 per diluted share) in Q1 2014.
  • 4HIV product sales grew 9% to $2.4 billion, driven by strong performance in single-tablet regimens such as Stribild and Complera/Eviplera.
  • 5The company's cash, cash equivalents, and marketable securities stood at $14.5 billion as of March 31, 2015, indicating a strong liquidity position.
  • 6Gilead completed a $3.0 billion stock repurchase program and announced a new $15.0 billion authorization, alongside initiating its first quarterly dividend of $0.43 per share.
  • 7Product gross margin improved to 88% from 83% in the prior year's quarter, attributed to a favorable product mix.

Frequently Asked Questions

The primary driver of Gilead's revenue growth in the first quarter of 2015 was the exceptional performance of its Hepatitis C (HCV) products, Harvoni and Sovaldi. These drugs generated $4.6 billion in sales, more than doubling from the previous year and significantly contributing to the overall 52% increase in total revenues.

Gilead's HIV product sales showed solid growth, increasing by 9% year-over-year to $2.4 billion. This growth was primarily driven by strong demand for its single-tablet regimens, including Stribild, which saw a 66% increase in sales, and Complera/Eviplera, which grew by 27%.

Gilead demonstrated strong financial health with $14.5 billion in cash, cash equivalents, and marketable securities as of March 31, 2015. The company is actively returning capital to shareholders by completing a $3.0 billion stock repurchase program and initiating a new $15.0 billion repurchase authorization, as well as commencing its first quarterly dividend payment.

Yes, Gilead faces ongoing litigation related to its HCV products, particularly Sovaldi and Harvoni, involving patent disputes with entities like Idenix Pharmaceuticals and AbbVie, as well as potential claims from Merck. Additionally, the company faces ongoing generic competition challenges for its HIV products and is subject to pricing pressures and reimbursement uncertainties in various global markets. The significant concentration of revenue from HCV and HIV products also presents a risk if demand or pricing were to change.